Evidence map›Paper›PMID 34847240›Full record

SynthesisThe Cochrane database of systematic reviews2021

Pharmacotherapy for smoking cessation: effects by subgroup defined by genetically informed biomarkers.

Ewoud Schuit, Orestis A Panagiotou, Marcus R Munafò, Derrick A Bennett, Andrew W Bergen, Sean P David

Abstract readSystematic ReviewRetraction Notice
PubMed Full text at PMC Publisher
In one paragraph

Synthesis in The Cochrane database of systematic reviews, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

6 authors.

Ewoud SchuitMeta-Research Innovation Center at Stanford (METRICS), Stanford University, Stanford, CA, USA.
Orestis A PanagiotouDepartment of Health Services, Policy & Practice, School of Public Health, Brown University, Providence, RI, USA.
Marcus R MunafòSchool of Experimental Psychology and MRC Integrative Epidemiology Unit, University of Bristol, Bristol, UK.
Derrick A BennettClinical Trial Service Unit and Epidemiological Studies Unit, Nuffield Department of Population Health, University of Oxford, Oxford, UK.
Andrew W BergenBiorealm, Culver City, CA, USA.
Sean P DavidDivision of Primary Care and Population Health, Department of Medicine, Stanford University, Stanford, California, USA.

Funding

PROJECT 1 (LEADERSHIP CORE)U01DA020830 · UNIVERSITY OF CALIFORNIA SAN FRANCISCO · 2005 to 2005
$2.0M
NIDA NIH HHS R21 DA033813NIDA NIH HHS R43 DA041211NIDA NIH HHS RC2 DA028793NIDA NIH HHS U01 DA020830
6 · The paper itself

Abstract

This review has been withdrawn because it has been found to be in breach of the Cochrane Commercial Sponsorship policy clause 2:  'Individuals who are currently employed or where employed any time in the last three years by a company that has a real or potential financial interest in the outcome of the review (including but not limited to drug companies or medical device manufacturers); or who hold or have applied for a patent related to the review are prohibited from being Cochrane Review authors. In most cases, current or previous employment would be characterized by the affiliation statement made by the author at the title registration, protocol, or review stage of the review'.

Indexed as

Smoking CessationBiomarkersCombined Modality TherapyHumansTobacco Use Cessation DevicesBiomarkers

Identifiers

PMID34847240
PMCPMC8631711

What Socratic holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.